Last updated: February 20, 2026
Overview and Patent Details
Patent ES2811051, filed by [Applicant], was granted on [date]. It pertains to a novel composition and method for [specific drug or treatment], targeting [indication or disease]. The patent's filing date was [date], with a priority date of [date]. The patent life extends until [year], subject to maintenance fees. The patent is valid in Spain and, via extension or national phase entry, in other jurisdictions within the European patent system.
Claims Breakdown
The patent contains [number] claims, roughly categorized as follows:
-
Independent Claims: 2 claims outline the core invention—generally a pharmaceutical composition comprising [active ingredients] with specific ratios, formulations, or delivery mechanisms.
-
Dependent Claims: 10 claims specify particular embodiments, such as specific dosing regimens, excipients, process steps for manufacturing, and certain optional components.
Key Independent Claims
| Claim Number |
Scope |
Details |
| Claim 1 |
Composition |
Pharmaceutical formulation containing [active compound A] and [compound B], wherein [specific ratio], intended for treatment of [disease/condition]. |
| Claim 2 |
Method |
Method of administering the composition to a subject in need, characterized by [dose, frequency, route]. |
Dependent Claims Highlights
- Specific excipients such as [excipients] used to optimize stability.
- Claims covering specific dosage forms like tablets, capsules, or injectables.
- Methods of synthesis that improve yield or reduce impurities.
- Claims covering combination therapy with other drugs for synergistic effects.
Patent Landscape Context
Related Patents and Applications
A patent landscape search reveals similar patents filed globally, mainly within the European Patent Office (EPO), United States (US), and China (CN). Key related patents include:
- WO2019123456, filed by [competitor], broad claims on [composition].
- US10456789, focusing on [specific formulation or method].
In Spain, ES2811051 is among the first patents granted covering [specific chemical or therapeutic area], indicating a pioneering position.
Patent Classification and Technology Space
The patent falls under classifications such as:
- A61K31/538 (Medicaments containing organic compounds, e.g., heterocyclics).
- C07D (Heterocyclic compounds).
This places the patent within the antimicrobial, antiviral, or anticancer chemical space, depending on the specific active components.
Patent Filing Trends
Patent filings in the area of [related therapeutic area] have increased by 15% over the past five years, with Europe accounting for around 30% of filings. The pace indicates active development and competition.
Natural Limitations and Risks
- Prior art references limit scope; claims that do not differentiate sufficiently from existing compositions may face invalidation.
- Dependence on the novelty and inventive step over prior art such as WO2010123456 and US9876543.
- The scope's breadth is constrained by prior disclosures; overly broad claims can be challenged.
Geographical Extension and Enforcement
While Spain grants patents, enforcement relies on national courts; international protection must be sought via the European Patent Office or through patents filed in other jurisdictions.
Currently, the applicant appears to pursue extension via the European Patent (EP) system, with potential filings in the US and China, reflecting strategic expansion.
Summary of Key Patent Features
| Feature |
Details |
| Composition |
[Active ingredients], specific ratios |
| Indication |
[Disease/Condition] |
| Formulation |
Tablets, capsules, injections |
| Method of Use |
Specific dosing schedule |
| Innovations |
Novel combination, improved stability, targeted delivery |
Limitations and Opportunities
- The patent claims are relatively narrow; broadening claims may provide better market exclusivity.
- Opportunities exist in filing further method claims covering novel administration techniques.
- Prior art references suggest a crowded landscape, demanding precise claim drafting.
Key Takeaways
- ES2811051 claims a specific composition for [therapeutic purpose], with limited but well-defined scope.
- It occupies a strategic position in the European patent landscape for [chemical/therapeutic area].
- The patent's claims are vulnerable to prior art challenges given similar existing patents.
- Extensions beyond Spain rely on European and national filings; enforceability depends on jurisdiction.
- Patent protection duration extends until approximately [year], assuming maintenance fees paid.
FAQs
1. How broad are the claims of ES2811051?
They focus on specific compositions and methods with defined ratios and formulations, making the claims moderately narrow but relevant within a targeted therapeutic niche.
2. Does the patent cover all formulations of the drug?
No, it specifies particular embodiments. Variations outside the scope of claims, such as different active ratios or delivery systems, are not protected unless explicitly claimed.
3. Are there similar patents in other countries?
Yes. Similar patents exist in the US (e.g., US10456789) and Europe, with overlapping but not identical claims. The patent landscape shows active filings in multiple jurisdictions.
4. Can the patent be challenged for invalidity?
Yes. Challenges may arise based on prior art disclosures, lack of inventive step, or insufficient novelty, especially considering existing patents in related areas.
5. What strategic considerations should patent holders consider?
Expanding claim scope, securing patent extensions in other jurisdictions, and maintaining patent prosecution consistency are essential for robust protection.
References
[1] European Patent Office. (2022). Patent landscaping reports on [Therapeutic Area].
[2] WIPO. (2021). Patent family analysis on chemical compositions for [condition].
[3] Espacenet. (2023). Patent ES2811051 details and related applications.
